GLORIA PHARMA.(SZ:002437)2025-07-16 12:15Group 1: Company Overview and Financial Performance - The company reported a revenue of 50 million yuan from self-paid products, with the exception of Lugu Peptide Injection, which is not covered by medical insurance [2] - The impact of the centralized procurement policy on the company's main products has stabilized, with a projected 40% increase in sales for Injection of Multiple Vitamins (12) in 2024 [3] - The company expects a slight decline or flat revenue compared to last year due to the effects of drug procurement policies [4] Group 2: Product Development and Market Strategy - The company plans to expand its product offerings in key areas such as vitamins, cardiovascular, and orthopedic fields [3] - New product launches and market expansions are anticipated, including the sales channels for Sitagliptin Metformin Sustained-Release Tablets and the introduction of Meloxicam Tablets [4] - The company aims to enhance its product pipeline through partnerships, acquisitions, and the introduction of differentiated products [5] Group 3: Research and Development Investment - The company's R&D investment is projected to be 3.97% of revenue in 2024, with plans to increase this ratio to align with industry standards [5] - Future acquisitions will focus on innovative and differentiated products, particularly in traditional Chinese medicine and generic drugs [6] Group 4: Financial Management and Cost Control - The company is committed to reducing costs and improving efficiency, aiming to keep sales, management, and financial expenses at a low level [4] - Cash received from investments at the end of Q1 2025 amounted to 261 million yuan, primarily from the redemption of financial products [6]